EU/3/10/814

About

On 26 November 2010, orphan designation (EU/3/10/814) was granted by the European Commission to Baxter Innovations GmbH, Austria, for recombinant human von Willebrand factor for the treatment of von Willebrand disease.

In May 2015, Baxter Innovations GmbH changed name to Baxalta Innovations GmbH.

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in July 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

Key facts

Active substance
Recombinant human von Willebrand factor
Disease / condition
treatment of von Willebrand disease
Date of decision
26/11/2010
Outcome
Withdrawn
Orphan decision number
EU/3/10/814

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Veyvondi at the time of marketing authorisation.

The sponsor formally requested the withdrawal of the orphan designation prior to the Committee's final opinion. More information is available in the PDF iconwithdrawal assessment report - orphan maintenance .

Sponsor's contact details

Baxalta Innovations GmbH
Industriestrasse 67
A – 1221 Vienna
Austria
Telephone: +43 1 20 100 247 2542
Telefax: +43 1 20 100 547 5990
E-mail: europe_biosci_globalra@baxalta.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating